CD123 is a biomarker for targeted therapy in certain diseases, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML) and acute lymphoblastic …

The interleukin-3 receptor (CD123) is a molecule found on cells which helps transmit the signal of interleukin-3, a soluble cytokine important in the immune system. The gene coding for the …

CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid …

Emerging studies demonstrate that CD123, the interleukin 3 receptor alpha (IL-3Rα), is highly expressed in LSCs, while not normal hematopoietic stem cells (HSCs), and associates with …

2014年2月10日 · This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid …

2019年9月12日 · Importantly, CD123 is expressed at both the level of leukemic stem cells (LSCs) and more differentiated leukemic blasts, which makes CD123 an attractive therapeutic target. …

CD123 targeting represents an effective therapeutic option for BPDCN patients and tagraxofusp, a drug based on a genetically engineered diphtheria toxin fused with IL-3, has shown robust …

2021年12月2日 · CD123 is a critical biomarker and promising immunotherapeutic target for children with relapsed or refractory AML, given its prevalent expression and enrichment in …

2021年5月17日 · Following the observation of interleukin 3 receptor α chain (IL-3Rα; CD123) upregulation on leukemia stem cells (LSCs) almost two decades ago, targeted treatment via …

2024年11月5日 · Vibecotamab is a CD3-CD123 bispecific engaging antibody with clinical activity in relapsed/refractory AML, particularly in low-blast disease. We therefore sought to evaluate …